Overview of CAR-T T erapy in Multiple Myeloma continued...
events (n = 16) and disease progression (n = 3). In November 2023, the FDA announced adding a warning to all CAR-T therapy for increased risk for T-cell malignancies due to safety reporting and post-marketing studies, although investigations are ongoing. T e prognosis of patients with refractory
MM and that have been exposed to at least three treatment lines is poor and response rates to traditional therapies remain low. Novel therapies such as chimeric antigen receptor T-cells (CAR-T) play a key role as they off er a personalized treatment that results in better overall response in patients with refractory or relapsing MM compared to standard regimens. However, a discussion with patients regarding the risks should occur prior to initiating therapy.
References: 1. Abecma (idecabtagene vicleucel) [prescribing
information]. Summit, NJ: Celgene Corporation; April 2024. 2. Attal M, Lauwers-Cances V, Hulin C, et al.
Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017; 376: 1311–20. 3. Berdeja JG, Madduri D, Usmani SZ, et al.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8. 4. Carvykti (ciltacabtagene autoleucel)
[prescribing information]. Horsham, PA: Janssen Biotech Inc; April 2024. 5. Cowan AJ, Green DJ, Kwok M, et al.
Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327(5):464-477. doi:10.1001/jama.2022.0003. 6. Feins S, Kong W, Williams EF, Milone
MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-S9. doi:10.1002/ajh.25418. 7. Fonseca R, Abouzaid S, Bonafede M, et al.
Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017;31(9):1915- 1921. doi:10.1038/leu.2016.380. 8. Gandhi UH, Cornell RF, Lakshman A, et
al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275.
doi:10.1038/s41375-019-0435-7. 9. Kumar SK, Callander NS, Adekola K, et al.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(12):1281-1301. doi:10.6004/ jnccn.2023.0061. 10. Kumar SK, Rajkumar V, Kyle RA, et
al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:
17046.doi:10.1038/nrdp.2017.46. 11. Kyle RA, Larson DR, T erneau TM, et al.
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Signifi cance. N Engl J Med. 2018;378(3):241-249. doi:10.1056/NEJMoa1709974. 12. Landgren O, Kyle RA, Pfeiff er RM, et
al. Monoclonal gammopathy of undetermined signifi cance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412–17. 13. Mateos MV, Weisel K, De Stefano V, et al.
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371- 1376. doi:10.1038/s41375-022-01531-2. 14. Munshi NC, Anderson LD Jr, Shah N, et al.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705- 716. doi:10.1056/NEJMoa2024850. 15. Ravindran A, Bartley AC, Holton SJ, et al.
Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6(10):e486. Published 2016 Oct 21. doi:10.1038/bcj.2016.100. 16. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;388(11):1002-1014. doi:10.1056/ NEJMoa2213614. 17. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335- 347. doi:10.1056/NEJMoa2303379. 18. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763. 19. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. Published 2021 Apr 6. doi:10.1038/s41408-021-00459-7. 20. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410- 427. doi:10.1016/S0140-6736(21)00135-5. 21. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187-1199. doi:10.2217/ imt.15.77.
22. US Food and Drug Administration (FDA). FDA drug safety communication: FDA investigating serious risk of T-cell malignancy following BCMA- directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies.
https://www.fda.gov/vaccines-blood-biologics/ safety-availability-biologics/fda-investigating- serious-risk-t-cell-malignancy-following-bcma- directed-or-cd19-directed-autologous. Published November 28, 2023. 23. Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. T e application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539-551. doi:10.1016/j.apsb.2018.03.001.
VALUABLE PHARMACY OWNER.
VALUABLE PHARMACIST. VALUABLE TECHNICIAN.
JOIN THE FORCE.
Impact your PROFESSION. Impact your FUTURE. Impact YOU.
MPA members save $250 on Annual Conference registration
morx.com 38 Missouri PHARMACIST | Volume 98, Issue II | Summer 2024
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
